Jaguar Gene Therapy Announces State-of-the-Art Commercial Gene Therapy Manufacturing Facility in North Carolina



LAKE FOREST, Illinois – (COMMERCIAL THREAD) –Jaguar gene therapy, a company accelerating breakthroughs in gene therapy for larger populations of patients with serious genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina. The 174,000 square foot facility is located approximately 20 miles from Jaguar’s Cary Process Science Lab, expanding the company’s presence in North Carolina. The facility, when fully converted to Jaguar’s gene therapy manufacturing specifications, will support future clinical and commercial production of the company’s initial programs, including: galactosemia; a specific genetic cause of autism; and type 1 diabetes. Jaguar is expected to create at least 200 jobs over the next few years as part of this expansion. The company will continue existing partnerships with the Contracted Development Manufacturing Organization (CDMO) and consider adding to its third-party network as needed to ensure dual sourcing and uninterrupted sourcing.

“We believe it is important to have the ability to manufacture multiple gene therapies, from process development to commercial GMP scale,” said Joe Nolan, CEO of Jaguar Gene Therapy. “This strategic investment will leverage the team’s proven expertise in CMC (chemistry, manufacturing and controls) and could allow Jaguar to potentially accelerate development times and deliver our therapies to patients and families of as safe and fast as possible.

At its commercial manufacturing facility in North Carolina, Jaguar plans to use the latest technology and purification techniques to increase product yields while reducing product impurities. The team’s experience in developing a scalable and commercially viable manufacturing process from the start has guided the company’s approach to investing early and often in manufacturing. In doing so, the company aims to be at the forefront of producing the purest and most potent gene therapy products.

“This new state-of-the-art manufacturing facility, which will be enhanced by our CDMO partnerships, will allow us to fully harness the unparalleled CMC expertise of our team as we aim to elevate the manufacturing of gene therapies,” said Andrew Knudten, MS, MBA, COO of Jaguar Gene Therapy. “Patient safety is our top priority, and this facility will give us better control of the manufacturing process to better ensure the highest level of purity in our products. ”

Jaguar will receive more than $ 7 million in state and local incentives as it expands into North Carolina, including an Employment Development Investment Grant (JDIG) that will provide more than $ 2 million. 12-year funding dollars. The North Carolina Biotechnology Center will offer a $ 100,000 Partnership Development Grant, awarded over three years based on job creation. Jaguar will also receive around $ 5 million in incentives from other state and local organizations. The company will invest more than $ 125 million in the new commercial manufacturing facility. Jaguar’s new manufacturing facility is owned and operated by Alexandria Real Estate Equities, Inc., the nation’s leading provider of real estate in the life sciences industry.

“North Carolina’s diverse presence in the life sciences continues to attract innovative biopharmaceutical companies,” said Governor Cooper. “Jaguar’s expansion into bioproduction at Research Triangle Park, along with its process science lab in Cary, strengthens North Carolina’s reputation as a premier location for these companies. ”

Several organizations have been valuable partners in supporting Jaguar’s expansion in North Carolina, including the North Carolina Department of Commerce, the North Carolina Economic Development Partnership, the North Carolina General Assembly North, North Carolina Community College System, County Durham, Greater Durham Chamber of Commerce, North Carolina Biotechnology. Center and Duke Energy.

About Jaguar Gene Therapy

Jaguar Gene Therapy, LLC is accelerating advances in gene therapy for patients with serious genetic diseases. Led by former AveXis leadership, Jaguar has a proven management team with the expertise to accelerate the development, manufacture and commercialization of novel gene therapy treatments. For more information, please visit and follow Jaguar gene therapy on LinkedIn.



Comments are closed.